Supply Chain Derisking: The Case For US-India Partnering Amid China Clout

With just 14% of active pharmaceutical ingredients estimated to be made in the US and China’s overall dominance in the space, a new study points to the pressing need for the US to address bottlenecks in the supply chain and proposes a string of approaches to partner with India in its de-risking efforts.

Partnering for supply chain resilience • Source: Shutterstock

The COVID-19 pandemic highlighted the risks of concentrated supply chains and the impact these can have on medicines security across countries, with ongoing geopolitical tensions and wars only further complicating present-day dynamics.

More from Supply Chain

India CDMOs Seek To Counter China With New Industry Body, See Europe As Ally

 
• By 

Indian CDMOs could consider collaborating with allies in Europe amid a focused effort via a new industry body to counter existing challenges like China’s manufacturing, regulatory and policy advantages and a shortage of funding and talent in the country even as talk of US tariffs throws a new spoke in the wheel

ITM Plots Logistics In GEP-NETs Ahead Of Drug Filing After Phase III Success

 

The company is building on its existing logistics and manufacturing for the radiopharmaceutical drug ITM-11, which delivered positive Phase III data.

Compounded GLP-1s For Obesity: Is The Genie Out Of The Bottle?

 
• By 

Patient demand for compounded versions of FDA-approved obesity drugs is unlikely to dissipate, even if semaglutide’s “shortage” status is resolved. The issue likely will continue to be a high-profile concern for the brand industry.

Zydus To Expand Takeda Supply Chain Role, Boost US Sales With CVS Tie-Up

 
• By 

A Zydus-Takeda joint venture is expected to supply more raw materials to the Japanese major. Meanwhile, a tie-up with CVS Caremark for the sitagliptin franchise is a boost for Zydus’s US sales while the company focuses R&D efforts on rare diseases like ALS and CAPS

More from Business

Can New US FDA Commissioner Makary Calm Agency During Turbulent Times?

 

Stakeholders are pleading for newly confirmed FDA Commissioner Martin Makary to stand up for the agency's high scientific standards and staff as he begins his term.

Deal Watch: Eyenovia Looks At New Direction In Proposed Merger With Betaliq

 
• By 

Plus deals involving Relmada/Trigone, Alvotech/Xbrane, OPKO Health/Entera, iOncologi/TargImmune and more.

Wave Aspires To Accelerated Approval In DMD With 48-Week Data

 
• By 

With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.